Detailed Action
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .1
Status of Claims
Claims 1-22 are pending. Based off the election of Group I and compound 627 by applicant, claims 1, 3-6, 8 and 15 are under examination.
Election/Restrictions
Claims 2,7,9-14 and 16-22 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group II and non-elected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 18 September 2026.
Applicant’s election of Group I, Claims 1-16 (formula III compounds and pharmaceutical compositions) in the reply filed on 18 September 2026 is acknowledged. Because Applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)).
The elected species is Compound 627, 2-(3-(5,7-Dichloro-3-chloro-1H-indol-1-yl)-4-fluorophenyl)-N-(2-hydroxyethyl) acetamide, shown in FIG. 1:
PNG
media_image1.png
144
344
media_image1.png
Greyscale
CAS Registry Number: 2958709-64-1,
2-fluoro-N-(2-hydroxyethyl)-5-(3,5,7-trichloro-1H-indol-1-yl)- Benzeneacetamide,
Compound 627 corresponds to a Compound of Formula III in which:
D is C-Rb3, and Rb3 is H; Rc1 is H; Rc2 is Cl; Ra2 is H; Ra3 is Cl; Ra4 is H; Ra5 is Cl; Rb1 is H; Rb2 is F; Rb4 is H;
V is -(CR2R3)k-U, wherein k is 1, R2 is H, R3 is H, and U is -C(=O)-NR10-,
wherein R10 is H; and
Z has Formula II, wherein u is 1, q is 1, X is absent, R5 is H, R6 is H, R7 is H, R8 is H, and Y is OR11, wherein R11 is H.
Information Disclosure Statement
The information disclosure statements (IDSs) submitted on July 28, 2024; August 5, 2024; September 22, 2024; March 6, 2025; December 23, 2025; and February 25, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
Specification
The disclosure is objected to because of the following informalities:
The specification recites at multiple occurrence but in particular, at page 6, line 18, “U is amide (-C(O)-NR10-) or an isostere thereof. . . . “ A comma appears to be missing between “amide” and (-C(O)-NR10-). The Examiner presumes amide and -C(=O)-NR10- are two distinct groups, where in the Attorney response dated Sept 18, 2026, Applicant elected species compound 627 where “U is -C(=O)-NR10-”.
Clarification and amendment of the specification is required, either to confirm this interpretation is correct, or whether amide and (-C(O)-NR10-) are meant to be a single group. If the two are terms are supposed to be a single group, amendment to put a dash (or other designation) between amide and (-C(O)-NR10-), to read “amide-(-C(O)-NR10-)” is required to indicate they are not two distinct groups, but a single group.
Appropriate correction is required.
Claim Interpretation
Note the elected species Compound 627 detailed above is NOT supported by claims 1, 3-6, 8 and 15, as it claims Rb3, Rc1, Ra2, Ra4, Rb1 and Rb4 are hydrogen.
The definition of Ra2-Ra5, R1-Rb4, Rc1and Rc2 in claim 1 does not list hydrogen. It claims Ra2-Ra5, R1-Rb4, Rc1and Rc2 “are each independently a substituent selected from alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy. . . . “
The organic chemistry definition of substituent excludes hydrogen, as it is defined as “[a]n atom or group other than hydrogen on a molecule. (The atom or group has substituted for the missing hydrogen.)” See UCLA Website, Illustrated Glossary of Organic Chemistry. Accessed October 17, 2026.2
Note that Claim 1 recites the indefinite proviso limitation in the last line of claim 1 stating when D is -Rb3, Rc1 is hydrogen. . . . Despite this proviso, the claims are examined where Ra2-Ra5, R1-Rb4, Rc1and Rc2 “are each independently a substituent selected from alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy. . . . “ and cannot be hydrogen, despite the statement of the last line of claim 1.
Closest Prior Art
The closest prior art is CAS RN 2306361-67-9 of WO 2019073471 A1, published 2019-04-18. See Figure 19-2, page 25/36 of the Substitute Sheet, reproduced below.
PNG
media_image2.png
202
274
media_image2.png
Greyscale
The above compound of Figure 19-2 differs from the claimed invention, where at a position equivalent to where D is CRb3, where equivalent to the Rb3 position, as well equivalent positions for Rb1, Rb4, Rc1, Rc2 and Ra2, there are hydrogens. Examined claim 1 excludes hydrogen from the definition of Rb3, Rb1, Rb4, Rc1, Rc2 and Ra2.
Claim Rejections - 35 USC § 112(a)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 3-6, 8 and 15 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Claim 1 recites a compound of formula III, where D, V, k, R2, R3, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14, U, X, Y, Z, formula II, u, q, Ra2-Ra5, Rb1-Rb4, Rc1 and Rc2 are broadly claimed therein.
Certain narrower embodiments of the claimed invention are presented in dependent claims 3-6, 8 and 15. Some of these claims further limit the claimed groups and substituents as detailed therein. However, limiting dependent claims 3-6, 8 and 15 do not correct the lack of written description, as they only further limit certain groups such as D, Rb1-Rb4, Ra2-Ra5, Ra3 and Ra5, X and Y, as well as where Z is formula II of claim 1.
The Supporting Disclosure
Applicants’ supporting disclosure contains certain descriptions and embodiments of the compounds of the invention.
In the present case, the important factors leading to a conclusion of inadequate written description is the absence of sufficient working examples of the invention as claimed, and the lack of predictability in the art.
In the present case there is no disclosure of compounds having the broad and full scope of claim 1. In fact, the scope of compounds that provide adequate written description are the compounds Fig. 1 of the drawings of the specification.
In contrast to the broad claimed scope of claim 1 and the groups and substituents claimed therein, the supporting disclosure is limited to the compounds of Fig. 1, where such compounds are not only narrower than the claimed scope but also not properly claimed (in particular to the groups, Ra2-Ra5, Rb1-Rb4, Rc1 and Rc2 which are hydrogens in said Fig. 1 compounds, see below).
Per Fig. 1 of the specification (drawing pages 1/23 to 2/23), the following compounds that fall within the scope of claim 1, formula III are compounds 421-6, 498-502, 552, 627 (elected species), 649, 661-663, 503-507, 512-514, 519, 526, 527 and 541. It is noted the compounds of Fig. 1 are limited to compounds where
D is limited to N or CH2 (i.e., CRb3 where Rb3 is limited to CH3);
Rc1 is limited to hydrogen;
Rc2 is limited to Cl, CF3 and methyl;
Ra2 is limited to hydrogen;
Ra3 is limited to F or Cl;
Ra4 is limited to H;
Ra5 is limited to Cl;
Rb1 is H;
Rb2 is limited to F, when D is C-H; Rb2 is limited to H, when D is N;
V-Z is limited to the following:
PNG
media_image3.png
60
105
media_image3.png
Greyscale
PNG
media_image4.png
74
106
media_image4.png
Greyscale
PNG
media_image5.png
72
102
media_image5.png
Greyscale
PNG
media_image6.png
50
112
media_image6.png
Greyscale
PNG
media_image7.png
74
108
media_image7.png
Greyscale
PNG
media_image8.png
76
106
media_image8.png
Greyscale
PNG
media_image9.png
74
112
media_image9.png
Greyscale
PNG
media_image10.png
58
114
media_image10.png
Greyscale
PNG
media_image11.png
58
106
media_image11.png
Greyscale
PNG
media_image12.png
52
190
media_image12.png
Greyscale
PNG
media_image13.png
76
120
media_image13.png
Greyscale
and
PNG
media_image14.png
56
110
media_image14.png
Greyscale
.
In contrast, claim 1 formula III broadly claims Rc1, Rc2, Ra2,Ra3, Ra4, Ra5, Rb2, Rb3, Rb4 V and Z far broader than the described and supported scope of the specification at Fig. 1. Further, unlike the compounds of Fig. 1, formula III of claim 1 excludes hydrogen atoms for Ra2-Ra5, Rb1-Rb4, Rc1 and Rc2.
Further, Table 1, starting at page 62 bridging to page 63, only identifies 15 compounds to demonstrate TRPV1 and potassium channel (Kv7.2/7.3) IC50 activity (µM), in particular compounds 421-6, 414, 415, 47, 541, 552, 627 (elected species), 533 racemic mixture, 417-4 569, 573, 649, 661, 662 and 663.
Limiting dependent claims 3-6, 8 and 15 do not correct the lack of written description, as they only further limit certain groups such as D, Rb1-Rb4, Ra2-Ra5, Ra3 and Ra5, X and Y, as well as where Z is formula II of claim 1.
Applicant’s disclosure of the compounds of Fig. 1, is not a sufficient representation of all the claimed compounds of claim 1 (and rejected dependent claims) as presently pending.
Other than the working examples of the specification (Fig. 1 compounds, supported by Table 1’s TRPV1 and potassium channel (Kv7.2/7.3) IC50 activity (µM)), Applicant has not reasonably described a scientific or “systematic” approach to synthesize the full scope of claim 1 and claims dependent. See MPEP 2163.02, the standard for determining compliance with the written description.3
Although Applicant has written description support for the compounds of Fig. 1, Applicant has not provided reasonably provided a description the support the broader scope of the claimed compounds of formula I.
Applicant has not adequately described the invention for the breadth that is claimed. It thus appears that Applicant was not in possession of the claimed invention at the time the application was filed, the full scope of compounds of formula I, and that Applicant’s species do not support the claimed genus.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1, 3-6, 8 and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 3-6, 8 and 15 are rejected as depending from claim 1, where claim 1 is indefinite as follows.
Claim 1 recites “U is amide (-C(O)-NR10-) or an isostere thereof. . . . “ A comma, or a dash, is missing between “amide” and (-C(O)-NR10-) rendering claim 1 indefinite. The Examiner presumes amide and -C(=O)-NR10- are two distinct groups. This interpretation is supported by the Attorney response dated Sept 18, 2026, where Applicant elected species compound 627 where “U is -C(=O)-NR10-,”.
The specification at page 6, line 18 recites the same indefinite phrase of “U is amide (-C(O)-NR10-)”.
Clarification and amendment of the specification and claim 1 is required, either to confirm amide and C(=O)-NR10- are two distinct groups by amending the claim to add a comma, or whether amide and (-C(O)-NR10-) are meant to be a single group. If the two are terms are supposed to be a single group, amendment to put a dash (or other designation) between amide and (-C(O)-NR10-), to read “amide-(-C(O)-NR10-)” is required. Regardless of either interpretation, claim 1 and claims dependent upon it are indefinite.
Claim 1 (as well as dependent claims 3-6, 8 and 15) is/are also indefinite as follows.
Claim 1 recites Ra2-Ra5, Rb1-Rb4, Rc1 and Rc2 “are each independently a substituent selected from alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, alkoxy. . . . “
It is clear that these groups are NOT hydrogen.
However, claim 1 contradicts this definition of Rc1, where it recites the proviso, when D is C-Rb3, Rc1 is hydrogen. . . .
Amendment of claim 1 to coincide the definition of Rc1 as to whether it can or cannot be a hydrogen is required, where Applicant can provide clear support for this definition of Rc1 in the originally filed specification.
Conclusion and Correspondence
In summary no claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WILLIAM LEE whose telephone number is (571)270-3876. The examiner can normally be reached M-F.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C. Milligan can be reached at (571) 270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/WILLIAM Y LEE/Examiner, Art Unit 1623
1 This application is a Continuation of PCT Patent Application No. PCT/IL2023/050058 having International filing date of January 18, 2023, which claims the benefit of priority under 35
USC §119(e) of U.S. Provisional Patent Application No. 63/300,293 filed on January 18, 2022.
2 See UCLA Website, Illustrated Glossary of Organic Chemistry. Accessed October 17, 2026, https://www.chem.ucla.edu/~harding/IGOC/S/substituent.html.
3 Whenever the issue arises, the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, inventor was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). An applicant shows that the inventor was in possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Lockwood v. Am. Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997). Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the inventor was in possession of the claimed invention. See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68,119 S.Ct. 304,312, 48 USPQ2d 1641, 1647 (1998); Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997); Amgen, Inc. v. Chugai Pharm., 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it"